SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biao luo who wrote (3174)12/6/1997 10:27:00 PM
From: Izzy  Read Replies (3) of 6136
 
Biao, what was your point in posting on the AGPH thread and then reposting your note on the VRTX thread? Are you trying to score kudos from someone? If you have concrete info and documentation to support your statements, then post the article here so that we call all read it. Otherwise, it appears that you are providing misinformation. With an estimated 30% failure rate of the VRTX PI so far (besides the high reported drug side-effects), I understand that VRTX/GLX cannot even get people to enroll in its USA clinical trials. Their drug is a dog and you know it. I even doubt that it will come to market, and, if it does, I sure as hell won't prescribe it unless there is clear proof that it is a superior PI to all others on the market at that time, which I seriously doubt. I had owned VRTX but sold to buy AGPH. You don't even own AGPH. So, bug off or post something that is truthful and documented.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext